Peritoneal cancer vaccine - AVAX Technologies
Latest Information Update: 31 Dec 2021
At a glance
- Originator AVAX Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peritoneal cancer
Most Recent Events
- 17 Mar 2008 Discontinued - Phase-I for Peritoneal cancer in France (Parenteral)
- 10 Aug 2005 Phase-I clinical trials in Peritoneal cancer in France (Parenteral)